These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38630497)

  • 1. Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
    Wong YJ; Chen VL; Abdulhamid A; Tosetti G; Navadurong H; Kaewdech A; Cristiu J; Song M; Devan P; Tiong KLA; Neo JE; Prasoppokakorn T; Sripongpun P; Stedman CAM; Treeprasertsuk S; Primignani M; Ngu JH; Abraldes JG
    Hepatology; 2024 Apr; ():. PubMed ID: 38630497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.
    Gawrieh S; Vilar-Gomez E; Wilson LA; Pike F; Kleiner DE; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Kowdley KV; Hameed B; Tonascia J; Loomba R; Sanyal AJ; Chalasani N;
    J Hepatol; 2024 Oct; 81(4):600-608. PubMed ID: 38762169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
    Thorhauge KH; Semmler G; Johansen S; Lindvig KP; Kjærgaard M; Hansen JK; Torp N; Hansen CD; Andersen P; Hofer BS; Gu W; Israelsen M; Mandorfer M; Reiberger T; Trebicka J; Thiele M; Krag A;
    J Hepatol; 2024 Jul; 81(1):23-32. PubMed ID: 38428644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
    Zhou XD; Kim SU; Yip TC; Petta S; Nakajima A; Tsochatzis E; Boursier J; Bugianesi E; Hagström H; Chan WK; Romero-Gomez M; Calleja JL; de Lédinghen V; Castéra L; Sanyal AJ; Goh GB; Newsome PN; Fan J; Lai M; Fournier-Poizat C; Lee HW; Wong GL; Armandi A; Shang Y; Pennisi G; Llop E; Yoneda M; Saint-Loup M; Canivet CM; Lara-Romero C; Gallego-Duràn R; Asgharpour A; Teh KK; Mahgoub S; Chan MS; Lin H; Liu WY; Targher G; Byrne CD; Wong VW; Zheng MH;
    Gut; 2024 Oct; 73(11):1883-1892. PubMed ID: 39089860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease.
    Pons M; Simón-Talero M; Millán L; Ventura-Cots M; Santos B; Augustin S; Genescà J
    Dig Liver Dis; 2016 Oct; 48(10):1214-9. PubMed ID: 27388262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
    Semmler G; Yang Z; Fritz L; Köck F; Hofer BS; Balcar L; Hartl L; Jachs M; Stopfer K; Schedlbauer A; Neumayer D; Maurer J; Müllner-Bucsics T; Simbrunner B; Scheiner B; Trauner M; Mandorfer M; Reiberger T; Bauer DJM
    Gastroenterology; 2023 Oct; 165(4):1041-1052. PubMed ID: 37442301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
    Wong YJ; Li J; Liu C; Chen Z; Chan YH; Putera M; Teh KB; Ang TL; Zhao L; Yan Z; Kumar R; Li X; Qi X
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1043-1051. PubMed ID: 35253271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    Yu H; Huang Y; Li M; Jiang H; Yang B; Xi X; Smayi A; Wu B; Yang Y
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2169-2181. PubMed ID: 38946401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
    Dallio M; Romeo M; Vaia P; Auletta S; Mammone S; Cipullo M; Sapio L; Ragone A; Niosi M; Naviglio S; Federico A
    World J Gastroenterol; 2024 Feb; 30(7):685-704. PubMed ID: 38515952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease.
    Margini C; Murgia G; Stirnimann G; De Gottardi A; Semmo N; Casu S; Bosch J; Dufour JF; Berzigotti A
    Hepatol Commun; 2018 Aug; 2(8):929-940. PubMed ID: 30094404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
    Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
    Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive tests for clinically significant portal hypertension after HCV cure.
    Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
    J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals.
    Pons M; Santos B; Simón-Talero M; Ventura-Cots M; Riveiro-Barciela M; Esteban R; Augustin S; Genescà J
    Therap Adv Gastroenterol; 2017 Aug; 10(8):619-629. PubMed ID: 28835776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease.
    Mendoza Y; Cocciolillo S; Murgia G; Chen T; Margini C; Sebastiani G; Berzigotti A
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3017-3025.e6. PubMed ID: 32289534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
    Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
    Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.
    Wu S; Kong Y; Piao H; Jiang W; Xie W; Chen Y; Lu L; Ma A; Xie S; Ding H; Shang J; Zhang X; Feng B; Han T; Xu X; Huo L; Cheng J; Li H; Wu X; Zhou J; Sun Y; Ou X; Zhang H; You H; Jia J
    Liver Int; 2018 Jun; 38(6):1045-1054. PubMed ID: 29119705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.
    Elhence A; Anand A; Biswas S; Vaishnav M; Yadav R; Das P; Panwar R; Agarwal S; Gamanagatti S; Kumar R; Shalimar
    Dig Dis Sci; 2023 Mar; 68(3):1016-1025. PubMed ID: 35670897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.
    Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
    Liver Int; 2019 Jan; 39(1):127-135. PubMed ID: 30107095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.
    Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
    Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.